Skip to main content

COVID-19 Topic Center

Diffuse Large B-Cell Lymphoma News

News
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at an intended dose intensity of 80% or higher was independently associated with an increased risk of hospitalization for infection in a cohort of older patients with diffuse large B-cell lymphoma (DLBCL), according…
News
Although regimens such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) cure nearly 60% of patients with diffuse large B-cell lymphoma (DLBCL), many patients who do not respond to or relapse after initial therapy succumb to their disease. Consequently, more…
News
The optimal dose of selinexor in patients with diffuse large B-cell lymphoma (DLBCL) is 60 mg twice weekly, according to a study published online ahead of print in the journal Cancer Chemotherapy and Pharmacology.  “Simulations of the safety and efficacy exposure-response models suggested that,…
News
Neurologic toxicities from treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) increased total health care costs more than $70,000 on average for US patients, according to a study published recently in American Health & Drug Benefits.  “This is the first study of the…
News
Per-patient-per-year (PPPY) costs for diffuse large B-cell lymphoma (DLBCL) in the United States are considerable, with many patients requiring treatment beyond their first line of therapy, according to a real-world study published online ahead of print in The Oncologist.  “Most incident and…
News
For patients with high-risk diffuse large B-cell lymphoma (DLBCL) who are younger and fit, R-CODOX-M/R-IVAC is a feasible and effective regimen, researchers reported in the Annals of Oncology.  “Outcomes for patients with high-risk DLBCL treated with R-CHOP chemotherapy are suboptimal but, to…
News
Adding polatuzumab vedotin (pola) to bendamustine + rituximab (BR) is cost-effective compared with BR alone in patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), according to a study published in the Journal of Comparative Effectiveness Research.  “…
News
Although real-world patients who received chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) showed better response rates, progression-free survival (PFS), and overall survival (OS) compared with past patients who received non-CAR-T…
News
According to a study that looked at improving treatment for patients with diffuse large B-cell lymphoma (DLBCL), skipping radiation and receiving less chemotherapy may become the new standard of care. "We serve this population, and tolerance to the treatment is important to them," Daniel Persky,…
News
According to a study in Reports of Practical Oncology & Radiotherapy that examined radiotherapy response differences among HIV positive (HIV +) patients who were also diagnosed with diffuse large B-cell lymphoma (DLBCL), researchers found radiotherapy did not impact survival or progression in…
Back to Top